Patient in China achieves complete remission from leukemia after CAR T-Cell therapy

Share This Post

Feb 2022: In China, a patient whose life was on the verge of ending was entirely healed of leukaemia thanks to CAR T-cell therapy, which stimulated the immune system. All cancer cells vanished swiftly in the first study of its kind. Immune-mediated therapy, which was pioneered in the United States by ACGT scientists such as Dr. Carl June of the University of Pennsylvania and Dr. Michel Sadelain of Memorial-Sloan Kettering Cancer Center, among others, is rapidly proving more and more successful in human trials with thousands of patients.

After being treated with CAR T-cell therapy, a middle-aged woman was reportedly cured of leukaemia. “The cancer cells in her body have vanished. Professor Qian Cheng, director of the Bio-Treatment Center at the hospital in Chongqing, said, “She is the first patient who has been entirely cured of the condition via gene therapy.”
Leukemia has been diagnosed in roughly four million people in China. CAR T treatment is a gene therapy that uses modified T cells to fight cancer cells in leukaemia patients. Most patients are treated with chemotherapy or bone marrow transplants. “CAR T therapy is a far better alternative,” Professor Qian said, “since it can lower expenditures by at least 30% compared to bone marrow transplants and is more likely to lead to a cure.”

According to Professor Qian, six other patients getting gene therapy at the same institution have improved their health. In China, CAR T gene therapy is still in the clinical trial stage, with only ten hospitals across the country having received it. The success has encouraged Qian’s team, which will continue to research doses in order to develop the novel medication.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

After amazing growth of CAR T-Cell therapy what's next
CAR T-Cell therapy

After amazing growth of CAR T-Cell therapy: what’s next?

CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient’s T-cells to attack cancer cells, demonstrating remarkable success in hematologic cancers. Advances in genetic engineering, regulatory support, and investment are driving further expansion. Researchers are now tackling the challenges of applying this therapy to solid tumors, aiming to enhance efficacy and accessibility, marking a new era in personalized cancer therapy and immunotherapy.

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy